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Case Report
Parvovirus B19 Associated Systemic Lupus 
Erythematosus in a Child with Sickle Cell 
Disease; a Diagnostic and Therapeutic Challenge
Marta Cabral1, Alexandra Dias2, Clara Abadesso3, Marta Conde1, Manuel Ferreira4, José Melo 
Gomes5, Helena Carreiro6
Abstract
Although sickle cell disease (SCD) and systemic lupus erythematosus (SLE) are two distinct and relative-
ly common chronic diseases, coexistence of these two conditions in the same patient appears to be rare. The au-
thors report an eight-year-old child with SCD who developed a severe form of parvovirus B19-associated SLE, 
with secondary severe immune hemolytic anemia related to drugs, Libman-Sacks endocarditis complicated 
by severe aortic regurgitation, dilated left ventricle with impaired function and myocardial ischemia, with fur-
ther decompensation culminating in cardiac arrest during an infectious intercurrence, which led to death. This 
patient displayed a broad spectrum of musculoskeletal, hematologic and cardiovascular complications, which 
could be associated with either SCD or SLE. Because of a substantial overlap between the clinical manifesta-
tions of these two disorders, the diagnosis of SLE in a patient with a previously known diagnosis of SCD may be 
difficult and is often delayed. Our report illustrates the importance of considering other disease processes, like 
autoimmune diseases when clinical features or its evolution are atypical of SCD and emphasizes some of the 
diagnostic difficulties encountered during the diagnosis and management of these patients.
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Introduction
Sickle cell disease (SCD) is a genetic disor-
der caused by a single amino acid mutation in the 
hemoglobin gene. Its clinical manifestations range 
from an asymptomatic state detected only by rou-
tine hematologic testing to a chronic triad of recur-
rent painful vasoocclusive episodes (complicated 
by progressive organ damage), hemolytic anemia 
and a predisposition to severe infections [1,2]. 
Prominent late complications of SCD include 
avascular necrosis of bone, progressive renal im-
pairment, leg ulcerations, proliferative retinopathy 
and cerebrovascular accidents[1]. Systemic lupus 
erythematosus (SLE) is a chronic autoimmune 
disease with an unpredictable clinical presentation 
and course [2]. The hallmark of SLE is the multi-
system involvement, with prominent cutaneous, 
musculoskeletal, hematological, renal and neuro-
logic manifestations [1]. The classification of SLE 
is made when a patient fulfills at least four of the 11 
revised criteria established by the American Col-
lege of Rheumatology (ACR) in 1997. Fever, ar-
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thralgia/arthritis and myalgia are common in both conditions 
[3,4].  Additionally, both diseases commonly affect the renal, 
cardiovascular and central nervous systems [4]. Although the 
etiology of this two conditions is different, their coexistence 
has been rarely reported [1-5]. 
The authors report a patient with SCD who developed a 
severe and fatal form of SLE and emphasize some of the diag-
nostic difficulties encountered during his diagnosis and treat-
ment.
Case report
An eight-year-old boy from healthy African and non-
consanguineous parents, had diagnosis of moderate-to-severe 
SCD (Hb SS) since 11-month-old, with a long history of mul-
tiple painful vasoocclusive crises and severe bacterial infec-
tions (osteomyelitis and three episodes of bacterial pneumo-
nia). Anemia had been treated intermittently with red blood 
cell transfusions. He presented with an acute illness charac-
terized by high fever (>39ºC), fatigue, hepatomegaly and in-
tense low back pain. Further evaluation showed: hemoglobin 
(Hgb) 4.6g/dl, hematocrit 12.9% and 15,000 reticulocytes/
mm³, 21,900 leukocytes/mm³, 21,000 platelets/mm3, C-re-
active protein 36.2 mg/dl, alanine aminotransferase 1878u/L, 
aspartate aminotransferase 767u/L, lactate dehydrogenase 
8524u/L, aPTT 40.1 seconds and D-dimers 16418μg/dL. 
Cardiology evaluation showed global cardiac chambers en-
largement, biventricular dysfunction with hypocontractility 
and mild pericardial effusion, without valve vegetations. He 
started intravenous (IV) ceftriaxone and required inotropic 
and oxygen support, multiple red blood cells and platelets 
transfusions. On day 8, already on clinical stability after septic 
shock, he had a massive intravascular hemolysis (Hgb 2.8g/
dl with hematocrit 3.9%, total bilirubin 8.9mg/dl and direct 
Coombs test +++ for IgG and C3d) after ceftriaxone infusion. 
This was interpreted as a severe immune hemolytic anemia, 
probably related to drugs. Ceftriaxone was suspended and he 
was treated successfully with high-dose IV methylpredniso-
lone. Despite clinical improvement, the low back pain and 
intermittent fever persisted for weeks. Further investigation 
revealed positive parvovirus B19 serology (IgM+IgG+), low 
C4 (5.6mg/dL), positive antinuclear antibody (ANA) titre 
1/320, anticardiolipin (aCL)(total titre: 29.3 u/mL, reference 
value (RV):<1,1) and anti- B2 glycoproteinI (anti- B2 GPI) 
antibodies (IgG 24.7 u/mL, RV:<10), while lupus anticoagu-
lant, anti-dsDNA, anti-Sm, anti-RNP, anti-SSA, anti-SSB and 
anti-neutrophil cytoplasm (ANCA) antibodies were nega-
tive. Erythrocyte sedimentation rate (ESR) was >140mm/1st 
hour. Lumbosacral  magnetic resonance imaging showed in-
flammatory myositis, without purulent defined collections. 
Drug-induced immune hemolytic anemia study confirmed 
the coexistence of a high titre of anti-ceftriaxone antibodies. 
Abdominal ultrasonography and myelogram showed no ab-
normalities.
After discharge and during one year of follow-up, he 
developed persistent fatigue, weight loss, intermittent poly-
arthralgia of the hands, generalized myalgia and anti-dsDNA 
became positive (18.3 u/mL). Mild pancytopenia (Hgb 
7.2g/dl, 139,000 platelets/mm3, 4,100 leukocytes/mm³) 
became persistent, as did high ESR (55-137mm/1st hour) 
and diagnosis of SLE was established. One year later, after 
another admission in the context of a lobar pneumonia with 
bilateral pleural effusion (sterile exudative pleural fluid with 
12,409cells/mm3 and positive ANA (1/640)), recurrent 
pericardial effusion and persistence of systemic and muscu-
loskeletal symptoms, treatment with hydroxyurea 30 mg/kg/
day, regular transfusions and oral prednisolone 0.5mg/kg/day 
was initiated. There was an extraordinary improvement of the 
cytopenias, systemic and musculoskeletal symptoms. Direct 
Coombs test became negative and ESR normalized. 
Three months later, suddenly he developed an ejection 
systolic murmur 5/6 degree. Transthoracic and transesopha-
geal echocardiography showed a mild aortic regurgitation 
with severe valvular dysfunction, with abnormalities compat-
ible with Libman-Sacks vegetations: valve masses of varying 
size (>2 mm in diameter), irregular borders and echodensity, 
firmly attached to the aortic valve surface, exhibiting no inde-
pendent motion (Figure 1). No vegetations suggestive of bac-
terial endocarditis were found. Enalapril 5mg/day was started 
and he remained relatively stable. One year later he developed 
a sudden onset of chest pain. Electrocardiogram was compat-
ible with myocardial ischemia (Figure 2) and echocardiogra-
phy showed severe aortic regurgitation with partial occlusion 
of one of the coronary arteries by an extension of the aortic 
valve verrucous lesions. 
He was treated with IV pulse methylprednisolone, an-
tibiotics and emergent coronary artery graft bypass surgery 
with associated aortic valve replacement by a mechanical 
prosthesis. Simultaneously, low molecular weight heparin 
was started. Macroscopic intraoperative examination revealed 
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signs of lupus carditis with poor ventricular function and the 
presence of bacterial vegetations on the aortic valve. Labora-
tory evaluation revealed Hgb 6.3 g/dl, 93,000 platelets/mm3, 
aPTT 50.3 seconds, positive ANA (1/640) and lupus anti-
coagulant (105 seconds, RV:<38), troponin 5.5 ng/dl and 
proBNP>10,000pg/mL. Post-operative echocardiography 
showed a dilated left ventricle with impaired function (ejec-
tion fraction: 15%), mild mitral regurgitation and a moderate 
peri-prosthetic aortic valve leak.
10
Figure 1. Pre-operative two-dimensional echocardiogram in the parasternal (long/short-axis) view 
showing diastolic flow reversal in the descending aorta, suggestive of severe aortic regurgitation.
Figure 2. Electrocardiogram performed 3 weeks after surgery, showing persistence of repolarisation 
abnormalities (ST depression and T-wave changes) compatible with myocardial ischemia.
Figure 1. Electrocardiogram performed 3 weeks after surgery, 
showing persistence of repolarisation abnormalities (ST depression 
and T-wave changes) compatible with myocardial ischemia.
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Figure 1. Pre-operative two-dimensional echocardiogram in the parasternal (long/short-axis) view 
showing diastolic flow reversal in the descending aorta, suggestive of severe aortic regurgitation.
Figure 2. Electrocardiogram performed 3 weeks after surgery, showing persistence of repolarisation 
abnormalities (ST depression and T-wave changes) compatible with myocardial ischemia.
Figure 2. Pre-operative two-dimensional echocardiogram in the 
parasternal (long/short-axis) view showing diastolic flow reversal 
in the descending aorta, suggestive of severe aortic regurgitation.
Lupus and drepanocytosis were well controlled with re-
mission of systemic and musculoskeletal symptoms as well as 
rare painful crises, while taking 30mg/kg/day hydroxyurea, 
0,5mg/kg/day prednisolone, warfarin (INR: 2-2,5), folic 
acid, captopril, furosemide, spironolactone and digoxin. 
One year later his clinical course was complicated by 
an extensive lobar pneumonia with further left ventricular 
dysfunction. The patient’s clinical condition significantly im-
proved after multiple transfusions, inotropics, IV antibiotics 
and oxygen. However, when he was already hemodynamically 
stabilized, he developed sudden cardiac arrest secondary to 
ventricular fibrillation. Cardiac resuscitation was attempted 
but ineffective, and the patient died.
Discussion
Although SLE and SCD are distinct diseases, both con-
ditions appear to be more prevalent among patients with an 
African ancestry and effectively, the patient reported supports 
that epidemiology [6]. Coexistence of SCD and SLE has 
been previously reported but, because of the limited number 
of cases from previous reports it is not possible to conclude 
whether SLE is more or less prevalent in patients with sickle 
cell hemoglobinopathies [1,3-5]. In fact, a MEDLINE search 
of the literature, from 1970 to 2004 revealed only 19 cases of 
coexisting SLE and SCD, from which only 14 fulfilled the 
1997 revised criteria of the ACR, which highlights the rarity 
of the overlap between these entities [1] and since both con-
ditions have a high prevalence in blacks, a protective effect of 
SCD in preventing SLE has been speculated [1,7]. On the 
other hand, the defective alternate pathway of the comple-
ment system, characteristic of the SCD patients, leading to a 
failure to eliminate bacterial antigens with subsequent forma-
tion of immune complexes, may predispose these patients to 
the development of autoimmune diseases like SLE, although 
the data on the latter are conflicting [2,3]. Furthermore, ANA 
positivity seems to be more common in patients with SCD 
(23%) than in the general population (10-15% of healthy chil-
dren) [2]. This may suggest an etiopathological link between 
these two entities.
The diagnosis of an underlying autoimmune disease may 
be particularly challenging in patients with SCD. These con-
ditions share a number of common manifestations, like joint 
involvement, pulmonary, cardiac and renal complications [2]. 
In our patient four of these main systems were affected: he de-
veloped musculoskeletal symptoms (intermittent polyarthral-
gia and lumbar myositis), bilateral pleural effusion, recurrent 
pericardial effusion and Libman-Sacks endocarditis reflecting 
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Infectious disease - first admission’s investigation 
Parvovirus B19 serology
Parvovirus B19 PCR (serum and medular blood)
Other serologic evaluations (Cytomegalovirus, Epstein-Barr virus, Adenovirus, Mycoplasma pneumoniae,
Clamydiapneumoniae, Human immunodeficiency virus (HIV)1 and 2, Hepatitis B virus (HBV), Hepatitis C 
virus (HCV), Toxoplasma gondii, BrucellaandLeishmania), Huddleson, VDRL, PCR for Enterovirus and 
Adenovirus (stool), PCR forLeishmania (medular blood)
Antistreptolysin O test (ASO) / anti-Dnase B
Tuberculin test 
Ziehl-Neelsen and Lowenstein (bronchial secretions and bronchoalveolar lavage), PCR Mycobacteria 
tuberculosis and atypical (medular blood)
ADA











(years-old) 8 8.5 9 9.5 10 11 11.5 Units (reference values)
ANA 1/320 1/640 1/640 1/640 1/640 1/160 1/160 -
Anti-dsDNAab Neg +(18.3) Neg +(24.9) Neg Neg Neg -
Anti-SMab Neg Neg Neg Neg Neg Neg Neg -
Anti-RNPab Neg Neg Neg Neg Neg Neg Neg -
Anti-SSA / SSBab Neg Neg Neg Neg Neg Neg Neg -
Anti-nucleossomeab - + +++ +++ ++ - - -
Anti-histone ab - - + Neg - - - -
C3 89 59 95 88 - 111 - -                         mg/dL (78-140)
C4 5.6 7.6 15.3 13 - 28.1 - - mg/dL (8-44)
CH50 - 35 41 45 - 46.9 - - U/mL (23-46)
Lupus anticoagulant 39.1 38.9 42.3 - 54.9 35.7 - - seconds (< 38)
aCPabtotal titre 


















(Positive: IgM or IgG>10)
DirectCoombstest +++ + + Neg Neg Neg - -
ESR >140 55 83 8 45 13 - -                               mm/1st hour
PCR 36.2 0.47 17.7 0.89 14.8 0.2 8.9 <0.05 mg/dL
Sickle cell disease and hematologic evaluation
Hemoglobin 2.8 7.2 6.0 8.8 6.3 9.7 10.2 9.9 g/dL
Fetal / S Hbg /25.4 - 2.6/65.9 4.6/85.7 4.8/36.8 13.4/75.1 - - %
White blood cell 21.9 3.1 2.7 6.3 16.4 3.5 2.1 2.5 X10³/µl
Platelets 21 93 156 78 93 94 117 112 X10³/µl
Others
Microalbuminuria 0.62 1.8 0.38 - - - - - mg/dL(<3.00)
Protein (24hours urine) - 64 - - - 245.3 - - mg/24h (<149.1)
Creatinine 0.4 0.3 0.3 0.5 0.6 0.6 0.6 0.6 mg/dL
Urea 30 17 12 19 27 38 35 26 mg/dL
Legend: VDRL: Venereal Disease Research Laboratory; ab: antibody; ESR: Erythrocyte sedimentation rate; PCR: C-reactive 
protein; Hbg: Hemoglobin
Table 1. First laboratory investigation for infectious and autoimmune diseases. Clinical and laboratory 

























Hospital admissions after 8y
Table 1. First laboratory investigation for infectious and autoimmune diseases. Clinical and laboratory evolution since the 
diagnosis of SCD and SLE coexistence.
VDRL: Venereal Disease Research Laboratory; ab: antibody; ESR: Erythrocyte sedimentation rate; PCR: C-reactive protein; Hbg: Hemoglobin
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pulmonary and cardiac involvement respectively, and he had 
one determination of elevated proteinuria (Table 1). Libman-
Sacks endocarditis is characterized by non-infective verrucous 
vegetations that develop mainly on the mitral valve, but also 
can be seen on other valves (e.g. aortic), as in our patient [8]. 
Although reported in a significant proportion of patients (30-
50%) in autopsy studies, symptomatic valvular disease with 
hemodynamic implications has been considered rare, but it 
was one of the severe comorbidities of our patient. 
For most patients, diagnosis of SCD is established early 
in life, so another diagnosis is not looked for when they pres-
ent with common rheumatological manifestations. This may 
contribute to a delay in the diagnosis of the second disorder, 
as it happened in our patient, whose definite diagnosis of SLE 
was established only one year after development of the first 
symptoms. But effectively, this patient fulfilled five criteria of 
the classification of SLE: positive ANA, other immunologic 
abnormalities (hypocomplementemia (C4), positive anti-ds-
DNA and antiphospholipid antibodies), serositis (pleural and 
pericardial effusion), immune hemolytic anemia and mild 
non-deforming arthritis or polyarthralgia. Moyssakis I. et al re-
ported a significant association between Libman-Sacks endo-
carditis and aPL syndrome, particularly associated to aCL an-
tibodies. Actually, development of this cardiac complication 
in our patient occurred concomitantly with the re-appearance 
of positive lupus anticoagulant; additionally, aCL antibodies 
were positive at the first presentation of SLE (Table 1).
Hematologic abnormalities are frequent in both SCD 
and SLE. Anemia is commonly present in both diseases but 
important differences between them exist with respect to the 
total white blood cell (WBC) and platelet count. The WBC 
count is characteristically elevated to 15.000/mm3 in patients 
with SCD, and thrombocytosis is also frequent [1]. In con-
trast, immune-mediated leukopenia and thrombocytopenia 
are common in SLE. As it was observed in our patient, one 
should suspect of SLE if there is a reduction in platelet or 
WBC count, and a positive direct Coombs test can confirm 
its immune origin. Although rare, this patient presented a drug 
(ceftriaxone)-induced immune hemolytic anemia. Curiously, 
Ogunbiyi et al reported a ceftriaxone-adverse reaction in an-
other eight-year-old African patient with SCD and SLE coex-
istence [7].
We have described a patient whose SLE symptoms be-
gan at the onset of an acute parvovirus B19 infection, and who 
shortly afterwards developed SLE. We could assume that this 
patient had a recent onset SLE with an intercurrent parvovirus 
B19 infection or that SLE had been precipitated by the virus. 
Similarities between their symptoms include the presence of 
fever, astenia, myalgia, polyarthritis, macular erythema and cy-
topenia (due to an arregenerative crisis, predominantly in pa-
tients with chronic hemolytic anemias such as SCD). Recent 
research has focused on the role of parvovirus B19 in the etio-
pathogenesis of SLE. In addition to the clinical similarity, par-
vovirus infection elicits autoantibodies to antigens commonly 
found in patients with SLE, including ANA, dsDNA and an-
tiphospholipid antibodies [9]. These symptoms and labora-
tory abnormalities are transient in some cases, yet persist in 
others, suggesting that the virus could in fact induce chronic 
autoimmunity [9]. In addition to our case, Hession et al re-
ported 9 cases in which parvovirus B19 infection produced 
transient SLE symptoms and 11 other cases in which clinical 
and serological manifestations persisted at least a year follow-
ing infection [9]. Additionally, Isa et al reported elevated levels 
of the Th1 cytokines such as interleukin 12 (IL-12) and IL-15 
at the time of the initial peak of parvovirus B19 viral load dur-
ing acute infection, and some of these patients had a sustained 
Th1 cytokine response 20 to 130 weeks after acute infection 
[10]. Moreover, there have been reports showing that Th1-
type cytokines might be involved in the development of SLE 
[11,12]. Thus, there is a possibility that persistently increased 
IL-12 and IL-15 after parvovirus B19 infection might be in-
volved in chronic SLE autoimmunity [13].
Once SLE is diagnosed, the risk/benefit ratio of each 
treatment must be carefully considered. Steroids are the main 
treatment for autoimmune conditions, and in particular for 
SLE. However, long-term administration of steroids is never 
free of complications, making patients with SCD more vulner-
able to life-threatening vasooclusive episodes and infections, 
especially if given in combination with immunosuppressive 
drugs [2,6,14]. The effects of steroids and/or immunosup-
pressive agents on the progression of SCD remain controver-
sial, and it would be beneficial to know whether SLE diagnosed 
in SCD patients have specific characteristics and/or a worse 
outcome, and whether the use of these agents are deleterious in 
patients with SCD [6]. For optimal management of these pa-
tients, rheumatologists and hematologists must work together 
closely and preventive measures such as chronic transfusions 
regimen and/or hydroxyurea  must be considered before start-
ing therapy [6,14], as was done in our patient.
Cabral M et al.
Annals of  Paediatric Rheumatology
76
Year  2012    Volume:1    Issue:1    71-76
In summary, in patients with coexisting SCD and SLE 
the recognition of the second is difficult and often delayed, 
but clinicians should be on the alert if the clinical behavior of 
the patient has changed, particularly with the appearance of 
pancytopenia, serositis or progressive neurological, renal or 
cardiac manifestations that are not consistent with classical 
SCD clinical profile or are unresponsive to the conventional 
treatment, as it was described in this report [1]. Early recogni-
tion of SLE in patients with SCD is important for beginning of 
appropriate therapy and eventual prevention of complications 
caused by their coexistence.
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